(:TZAC)

Dec 14, 2020 09:20 am ET
Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (“Reviva Holdings”), as the successor to Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and...
Nov 18, 2020 08:30 am ET
Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Shareholder Meeting Date to Approve the Business Combination
Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage...
Nov 04, 2020 04:05 pm ET
Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce the Appointment of Narayan Prabhu as Chief Financial Officer
Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage...
Jul 28, 2020 04:45 pm ET
MERGER ALERT - IFF, GSB, and TZAC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / July 28, 2020 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
Jul 21, 2020 07:54 am ET
Tenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Execution of Definitive Agreement and Plan of Merger for Business Combination
NEW YORK, July 21, 2020 /PRNewswire/ -- Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands ("Tenzing") (NASDAQ:  TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation ("Reviva") and a California-based clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases, announced today they have entered into a definitive agreement and plan of merger (the "Merger Agreement") for a business combination transaction
May 21, 2020 12:55 pm ET
Tenzing Acquisition Corp. Announces Extension of Deadline to Complete a Business Combination
NEW YORK, May 21, 2020 /PRNewswire/ -- Tenzing Acquisition Corp. (Nasdaq: TZACU, TZAC, TZACW) (the "Company"), a publicly-traded special purpose acquisition company, announced the vote by shareholders to extend the deadline to consummate an initial business combination from May 26, 2020 to July 27, 2020 (or September 28, 2020 if the Company has executed a definitive agreement for a business combination by July 27, 2020). Approximately 2,534,624 public shares were redeemed by existing stockholders in connection with the extension, leaving approximately $34,008,726 in cash in trust after redem

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.